Artificial Intelligence Supporting CAncer Patients Across Europe - the ASCAPE Project

NCT04879563 · tracked via the Priya Life Science Spain tracker

Sponsor

Region Örebro County

Phase

Phase 2

Started

2021-02-01

Last updated

2024-11-19

Condition(s) studied

Breast CancerProstate CancerQuality of LifeSurvivorshipToxicity

Investigational drug(s) / intervention(s)

ASCAPE-based follow-up strategy

ASCAPE-based follow-up strategy: Follow-up through ASCAPE platform including AI-based predictions for health-related QoL issues and suggestions for personalized interventions depending on the type of QoL issue that needs to be tackled. The ASCAPE-based follow-up strategy includes follow-up through validated QoL questionnaires, wearables for capturing active monitoring data, and mobile apps for answering the questionnaires and capturing potential health-related issues.

Study summary

ASCAPE (Artificial intelligence Supporting CAncer Patients across Europe) is a collaborative research project involving 15 partners from 7 countries, including academic medical centers, SMEs (small and medium-sized enterprises), research centers and universities, aiming to leverage the recent advances in Big Data and AI (Artificial Intelligence) to support cancer patients' Quality of Life (QoL) and health status. Specifically, ASCAPE aims to provide personalized- and AI-based predictions for QoL issues in breast- and prostate cancer patients as well as suggest potential interventions to their physicians.

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 875351.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

The patient selection process varies among the different study sites. Three Hospitals (Sismanogleio General Hospital Athens (SGHA), Örebro University Hospital (ÖUH), Uppsala University Hospital (UUH)) will include patients with newly diagnosed breast- (ÖUH, UUH) or prostate cancer (SGHA, ÖUH) who are eligible for curative treatment with surgery (breast cancer in ÖUH and UUH; prostate cancer in NKUA) or radiotherapy (prostate cancer; ÖUH). One Hospital (Barcelona) will include breast cancer survivors (at least 12 months after surgery or chemotherapy) with follow-up through the Hospital. Finally, CareAcross will include patients with breast- or prostate cancer through its online platform for patients seeking for the CareAcross services. Inclusion Criteria (breast cancer; ORB and Uppsala): * breast cancer diagnosis * no clinical evidence of metastatic disease * able for curative treatment with surgery with or without oncological treatment. Inclusion Criteria (breast cancer; Barcelona) * prior early breast cancer who are at follow-up with at least 12 months after surgery or chemotherapy (whichever occurred last). Inclusion Criteria (breast cancer; CareAcross) * breast cancer diagnosis (as per self-reported) irrespective of stage and treatment. Inclusion Criteria (prostate cancer; SGHA and ORB) * proostate cancer diagnosis * no clinical evidence of metastatic disease * able for curative treatment with surgery with or without oncological treatment (SGHA) or radiotherapy (with or without prior surgery) irrespectively the type of radiotherapy (external radiotherapy, brachytherapy, or combination). Inclusion Criteria (prostate cancer; CareAcross) * prostate cancer diagnosis (as per self-reported) irrespective of stage and treatment. Exclusion Criteria (common in all study sites): * inability to give informed consent * inability / no access to smartphones, applications or internet services * patients with known medical history of allergy to the wearable material.

Primary outcome measure(s)

Patients' experience using ASCAPE-based follow-up — At the end of intervention (month 12)
Patients' experience to be followed with the help of an AI-based system per se, patients' satisfaction with this type of follow-up, potential barriers and facilitators of using wearables during follow-up, and motivation for following interventions based on AI-based follow-up

Trial sites (5)

Facility	City	Region
Urology Department, Sismanogleio General Hospital	Athens	Greece
Oncology Department, Hospital Clínic de Barcelona	Barcelona	Spain
Department of Oncology, Örebro University Hospital	Örebro	Sweden
Department of Oncology, University Hospital of Uppsala	Uppsala	Sweden
CareAcross	London	United Kingdom

More Region Örebro County trials in Spain

Retention With Three Different Bonded Retainers a Multicenter, Randomized Controlled Trial With 5-year Follow-up Active, not recruiting

Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients Recruiting

Other trials for the same condition

Evaluation of the Epilepsy-related Quality of Life, Seizure-related Accidents and Validation of the Mjn-SERAS Solution in the Normalised Patient Environment with Real-World Data Recruiting

A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs Recruiting

Digital Tool for Psychological Support in Women With Breast Cancer Starting soon

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) Active, not recruiting

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04879563 on ClinicalTrials.gov ↗ ← All trials in Spain